Prot #1101-HEM-101: A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed or Refractory Hematologic Malignancies

Project: Research project

Project Details

StatusFinished
Effective start/end date9/8/17 → 9/8/20

Funding

  • Translational Drug Development, LLC (Prot #1101-HEM-101)
  • FORMA Therapeutics, Inc. (Prot #1101-HEM-101)